哮喘药物基因组学的全基因组关联研究进展  

Advances in Genome-Wide Association Study on Asthma Pharmacogenomics

作　　者：王钦 任洛[1] 刘恩梅[1] 

机构地区：[1]重庆医科大学附属儿童医院呼吸科,国家儿童健康与疾病临床医学研究中心,儿童发育疾病研究教育部重点实验室,儿科学重庆市重点实验室,重庆

出　　处：《临床医学进展》2024年第3期1724-1732,共9页Advances in Clinical Medicine

摘　　要：支气管哮喘(简称哮喘)是一种复杂的多因素疾病。哮喘患者对药物的治疗反应具有个体差异,部分原因由遗传因素决定。药物基因组学主要是研究人类基因组信息与药物反应之间的关系。全基因组关联研究(GWAS)可以分析大样本量及复杂疾病与基因的关联,是药物基因组学研究的新方法。目前,哮喘的GWAS已经指出一些具有潜在希望的基因变异。本文就抗哮喘药物治疗反应性相关GWAS的研究进行综述,以介绍哮喘药物基因组学的进展。Bronchial asthma is a complex multifactorial disease. Individual differences in the therapeutic response to medications in asthmatics are partly determined by genetic factors. The focus of pharmacogenomics is on the relationship between human genomic information and drug response. Genome-wide association studies (GWAS), which can analyze the relationship between complex diseases and genes in large sample sizes, are a novel approach to pharmacogenomic research. GWAS have identified some potentially promising genetic variants for asthma. This article provides a review of studies on GWAS related to therapeutic responsiveness to anti-asthma medications in order to present advances in asthma pharmacogenomics.

关 键 词：哮喘 药物基因组学 GWAS 

分 类 号：R56[医药卫生—呼吸系统]